» Articles » PMID: 10890986

Antibiotic Rashes in Children: a Survey in a Private Practice Setting

Overview
Journal Arch Dermatol
Specialty Dermatology
Date 2000 Jul 13
PMID 10890986
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To document the frequency and severity of various types of rashes seen with commonly used oral antibiotics in the pediatric outpatient setting.

Design: A retrospective review of 5923 patient records at a pediatric office.

Setting: A private group pediatric practice in northern Virginia with about 12,000 registered active patients.

Patients And Methods: Approximately 50% of the clinic medical records were reviewed. All children (defined as those aged 0-18 years in this study) identified on their medical records as having developed a rash following treatment with 1 or more of the commonly used oral antibiotics were included in the study. For further validation, a questionnaire about parental recollection of description of rash, other associated symptoms, physician verification, and outcome was mailed to families with children designated as being allergic to an antibiotic.

Results: On a prescription basis, significantly more rashes were documented for cefaclor (4.79%) compared with penicillins (2.72%), sulfonamides (3. 46%), and other cephalosporins (1.04%). Based on the number of patients for whom each group of antibiotic was prescribed, the documented frequencies of rashes were 12.3%, 7.4%, 8.5%, and 2.6% for cefaclor, penicillins, sulfonamides, and other cephalosporins, respectively. None of the children had rashes severe enough to require hospitalization.

Conclusions: In a review of almost 6000 records in a private pediatric primary care setting, rashes occurred in 7.3% of children who were given the commonly used oral antibiotics. Significantly more rashes were documented with cefaclor use than with use of any of the other oral antibiotics.

Citing Articles

Risk Stratification of Penicillin Allergy Labeled Children: A Cross-Sectional Study from Jordan.

Alsulaiman J, Kheirallah K, Alrawashdeh A, Saleh T, Obeidat M, Alawneh Y Ther Clin Risk Manag. 2024; 20:505-514.

PMID: 39188939 PMC: 11346476. DOI: 10.2147/TCRM.S464511.


Antibiotic Allergy De-Labeling: A Pathway against Antibiotic Resistance.

Dona I, Labella M, Bogas G, de Santa Maria R, Salas M, Ariza A Antibiotics (Basel). 2022; 11(8).

PMID: 36009924 PMC: 9404790. DOI: 10.3390/antibiotics11081055.


Factors Associated With Penicillin Allergy Labels in Electronic Health Records of Children in 2 Large US Pediatric Primary Care Networks.

Taylor M, Joerger T, Li Y, Scheurer M, Russo M, Gerber J JAMA Netw Open. 2022; 5(3):e222117.

PMID: 35285918 PMC: 9907342. DOI: 10.1001/jamanetworkopen.2022.2117.


Drug Allergy Delabeling Programs: Recent Strategies and Targeted Populations.

Anstey K, Tsao L, Otani I Clin Rev Allergy Immunol. 2022; 62(3):484-504.

PMID: 35031956 DOI: 10.1007/s12016-021-08913-x.


Severe Generalized Bullous Fixed Drug Eruption Treated with Cyclosporine: A Case Report and Literature Review.

Barootes H, Peebles E, Matsui D, Rieder M, Abuzgaia A, Mohammed J Case Rep Dermatol. 2021; 13(1):154-163.

PMID: 33790760 PMC: 7989674. DOI: 10.1159/000513469.